Drugs Made in America AcquisDMAAU
13F holders, Q2 2025 (June 30)9holders −6
1new positions
7sold out
1famous investor
$10.32avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Drugs Made in America Acquis (DMAAU) in their 13F filings, down 6 from Q1 2025. 1 opened new positions and 7 sold out. The largest holders were Rivernorth Capital Management, LLC ($4.3M), Context Capital Management, LLC ($2.6M) and Wolverine Asset Management LLC ($1.3M). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Drugs Made in America Acquis
- CUSIP
- G2847J120
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $310K |
| Exits | 7 | $23.1M |
All 13F filers, Q1 2025 → Q2 2025: 70,178 shares bought and 2,373,272 shares sold, net −2,303,094 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Rivernorth Capital Management, LLC | 0.24% | No change | 420,498 | $4.3M |
| Context Capital Management, LLC | 2.02% | No change | 250,000 | $2.6M |
| Wolverine Asset Management LLC | 0.10% | No change | 130,000 | $1.3M |
| Bulldog Investors, LLP | 0.15% | Reduce -56.0% | 57,300 | $591K |
| Clear Street LLC | 0.00% | Add +685.1% | 45,920 | $474K |
| Robinson Capital Management, LLC | 0.13% | New | 30,000 | $310K |
| Tuttle Capital Management, LLC | 0.85% | Reduce -50.0% | 20,000 | $206K |
| UBS Group AG | 0.00% | Add +0.6% | 18,385 | $190K |
| Citadel Advisors | 0.00% | Reduce -11.0% | 14,026 | $145K |
"% of holder's portfolio" is DMAAU's weight in each manager's 13F, not the share of Drugs Made in America Acquis the manager owns.